Return to All Resources

A clinical perspective on environmental, occupational, and lifestyle risk factors — and why earlier recognition starts with awareness.

• Bladder cancer risk factors are well established but can be missed in clinical practice.¹
• Approximately 5-15% of patients in the US who die of bladder cancer have strong occupational and environmental exposures, which can be an overlooked element of patient history.²
• Smoking tobacco, which accounts for 50-65% of all bladder cancer cases, is a significant modifiable risk factor, yet it is often under-discussed in this context.³
• Thorough history-taking can help identify high-risk patients.⁴
• A Finnish study (n=131) showed that time from symptoms to treatment (TURBT) was 78 days.⁵ Small, intentional shifts in questioning can meaningfully impact diagnostic timelines.

Bladder cancer is common, and many of its risk factors are well established.^1,6 Cancer screening tests, including history taking, can help identify some cancers early.⁴

Bladder cancer is the sixth most common cancer in the US, with over 84,000 new cases diagnosed each year.⁶ It’s more common in men, particularly in older adults with a history of smoking or occupational chemical exposure.⁷

Clinically, the disease presents in ways that may be attributed to more routine urologic conditions⁷:

• Blood in the urine, either visible or microscopic
• Urinary urgency, frequency, or irritation

Yet outcomes differ dramatically depending on when the disease is identified. Early-stage bladder cancer is highly treatable,⁷ while delayed diagnosis increases the likelihood of mortality.⁸

In many cases, a bladder cancer diagnosis becomes less surprising in retrospect. When environmental exposures, occupational history, smoking status, and symptom patterns are evaluated, certain cases begin to look less random and far more predictable.

How Occupational Exposure Shapes Long-term Risk

Occupational exposure remains an established — and often overlooked — risk factor for bladder cancer. Long-term contact with industrial chemicals such as aromatic amines (like benzidine and beta-naphthylamine) has been linked to increased risk across professions including^9,10:

• Firefighting
• Veterans
• Manufacturing
• Painting
• Trucking
• Hairdressers/barbers
• Roles involving dyes, rubber, leather, and textiles

One of the challenges is the significant lag between exposure and disease development. Bladder cancer may emerge decades after initial exposure, with some studies suggesting more than 30 years later. This can make the connection easy to miss during routine evaluation.¹¹

Compounding the issue, detailed occupational history is rarely captured, with rates that have been observed as low as 2-3%.¹² But identifying these risks does not require lengthy assessments — a few intentional screening questions about current and past work environments can uncover patterns that might otherwise go unrecognized.

Smoking As the Dominant Lifestyle Risk Factor

Smoking contributes to about half of all bladder cancers, and people who smoke are at least 3 times as likely to develop the disease compared to nonsmokers.⁹ While many smoking-related discussions focus heavily on lung cancer, the connection to bladder cancer is often underrecognized by both patients and providers.

 Importantly, risk does not disappear immediately after smoking cessation. Some studies showed that former smokers — even those with moderate smoking histories — can remain at elevated risk for more than 24 years after quitting.¹³ This creates an important opportunity for clinicians to broaden how they frame smoking and bladder cancer conversations in practice.

Positioning smoking as a risk factor not only for lung cancer but also for urologic cancers such as bladder cancer may help strengthen patient awareness and support more comprehensive risk assessment during routine care.

Bladder cancer risk develops through multiple factors over time, making comprehensive history-taking critical for identifying patients who may be at elevated risk.

Key considerations include^7,9:

• Age and gender: Risk increases with age and occurs more frequently in men.
• Chronic bladder irritation: Recurring urinary tract infections, prolonged catheter use, and ongoing inflammation may contribute to long-term bladder changes.
• Personal cancer history: Patients with a history of bladder cancer or other urothelial cancers involving the kidneys, ureters, or urethra are at an increased risk for recurrent or additional malignancies.
• Prior cancer treatment: Pelvic radiation and long-term use of certain chemotherapy agents, such as cyclophosphamide, are associated with a higher bladder cancer risk.
• Genetic predisposition: Certain inherited conditions and mutations, such as those that impair the body’s ability to process toxins, may increase susceptibility over time.

Taken together, these overlapping influences reinforce an important clinical reality: bladder cancer risk is cumulative, and meaningful risk assessment often depends on recognizing how multiple factors intersect through a patient’s lifetime.

Many high-risk patients move through the healthcare system without being flagged for further evaluation^14,15:

• Retired workers — who may be at risk for decades after exposure to chemicals linked to bladder cancer — may no longer associate past occupational exposures with current symptoms.
• Patients with lower-level or intermittent exposure histories can fall outside traditional screening assumptions.
• Women may experience delayed diagnosis when early symptoms such as hematuria are initially attributed to urinary tract infections or other benign conditions.

These patients may not self-identify as high risk, and most healthcare systems are not designed to identify them automatically. This creates a critical gap where targeted questioning and clinical pattern recognition can make a meaningful difference in earlier detection of bladder cancer.

A Call to Clinical Awareness

Earlier recognition of bladder cancer risk does not require complex screening tools or major workflow changes. In many cases, it starts with integrating a few questions about occupational exposure, smoking history, and long-term urinary symptoms into routine patient conversations. These small shifts can help identify patients who may benefit from earlier evaluation before symptoms progress or opportunities are missed.

Ultimately, earlier detection begins long before any test for bladder cancer is ordered. And as awareness improves, so does the potential to recognize patterns sooner and intervene earlier.

Dr. Sandeep Reddy is Chief Medical Officer at ImmunityBio, with extensive experience in oncology, precision medicine, and clinical care. He previously served as Chief Medical Officer at NantHealth and Caris Life Sciences and has contributed to more than 100 medical conference abstracts and 30 peer-reviewed publications.

References: 1. Bladder cancer causes, risk factors, & prevention. Memorial Sloan Kettering Cancer Center website. Accessed May 21, 2026. https://www.mskcc.org/cancer-care/types/bladder/bladder-prevention-risk-factors 2. National Cancer Institute. Bladder and other urothelial cancers screening (PDQ^®)–Health professional version. NIH National Cancer Institute website. Updated April 8, 2025. Accessed May 21, 2026. https://www.cancer.gov/types/bladder/hp/bladder-screening-pdq 3. Saginala K, Barsouk A, Aluru JS, Rawla P, Padala SA, Barsouk A. Epidemiology of bladder cancer. Med Sci (Basel). 2020;8(1):15. 4. National Cancer Institute. Cancer screening overview (PDQ®)—Patient version. NIH National Cancer Institute website. Updated October 20, 2023. Accessed June 25, 2026. https://www.cancer.gov/about-cancer/screening/patient-screening-overview-pdq 5. Sell V, Ettala O, Montoya Perez I, et al. Symptoms and diagnostic delays in bladder cancer with high risk of recurrence: results from a prospective FinnBladder 9 trial. World J Urol. 2020;38(4):1001-1007. 6. National Cancer Institute. SEER Training Modules. Bladder cancer: incidence and mortality. NIH National Cancer Institute website. Updated April 22, 2025. Accessed May 21, 2026. https://training.seer.cancer.gov/bladder/incidence.html 7. Bladder cancer. Mayo Clinic website. March 29, 2024. Accessed May 21, 2026. https://www.mayoclinic.org/diseases-conditions/bladder-cancer/symptoms-causes/syc-20356104 8. Hollenbeck BK, Dunn RL, Ye Z, et al. Delays in diagnosis and bladder cancer mortality. Cancer. 2010;116(22):5235-5242. 9. Bladder cancer: bladder cancer risk factors. American Cancer Society website. Revised March 12, 2024. Accessed May 21, 2026. https://www.cancer.org/cancer/types/bladder-cancer/causes-risks-prevention/risk-factors.html 10. Kronstedt S, Cathey J, Chiu CB, et al. Exposures and Bladder Cancer Risk Among Military Veterans: A Systematic Review and Meta-analysis. Urology. 2024;194:270-277. 11. Miyakawa M, Tachibana M, Miyakawa A, et al. Re-evaluation of the latent period of bladder cancer in dyestuff-plant workers in Japan. Int J Urol. 2001;8(8):423-430. 12. Politi BJ, Arena VC, Schwerha J, Sussman N. Occupational medical history taking: how are today’s physicians doing? A cross-sectional investigation of the frequency of occupational history taking by physicians in a major US teaching center. J Occup Environ Med. 2004;46(6):550-555. 13. Welty CJ, Wright JL, Hotaling JM, Bhatti P, Porter MP, White E. Persistence of urothelial carcinoma of the bladder risk among former smokers: results from a contemporary, prospective cohort study. Urol Oncol. 2014;32(1):25.e21-25.e2.4999999999999998E25. 14. Millerick-May ML, Wang L, Rice C, Rosenman KD. Ongoing risk of bladder cancer among former workers at the last benzidine manufacturing facility in the USA. Occup Environ Med. 2021;78(9):625-631. 15. Cohn JA, Vekhter B, Lyttle C, Steinberg GD, Large MC. Sex disparities in diagnosis of bladder cancer after initial presentation with hematuria: A nationwide claims-based investigation. Cancer. 2014;120(4):555-561.

US-ANK-260134 v1.0, June 2026.